Fiscal Year 2025 Guidance - CooperCompanies projects total revenue between $4,076 million and $4,096 million, representing organic growth of 4% to 4.5%[1] - CooperVision is expected to generate revenue between $2,734 million and $2,747 million, with organic growth of 4% to 5%[1] - CooperSurgical anticipates revenue between $1,343 million and $1,349 million, reflecting organic growth of 3% to 3.5%[1] - The company forecasts non-GAAP EPS to be in the range of $4.08 to $4.12[1] Q4 2025 Guidance - CooperCompanies estimates total revenue between $1,049 million and $1,069 million, indicating organic growth of 2% to 4%[1] - CooperVision's revenue is projected to be between $700 million and $713 million, with organic growth of 2% to 4%[1] - CooperSurgical expects revenue between $350 million and $356 million, showing organic growth of 2% to 4%[1] - The company predicts non-GAAP EPS to be between $1.10 and $1.14[1] Additional Information - Organic growth excludes the impact of acquisitions and discontinuations in the comparable period and is on a constant currency basis[2] - A reconciliation of non-GAAP measures to GAAP measures is available on the company's website[2] - The company has not provided reconciliation to GAAP for EPS guidance due to the difficulty in forecasting acquisition-related, integration, and restructuring charges and expenses[2]

Q2'26 Quarterly Results August 27, 2025 Safe Harbor and Other Information This presentation and associated commentary contain forward-looking statements regarding Veeva's expected future performance and, in particular, includes guidance, provided as of August 27, 2025, about Veeva's expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there ...

Financial Results Q2 FY 2026 As of August 27, 2025 ® CrowdStrike, Inc. All rights reserved. Please see the appendix included at the end of this presentation for a discussion of non-GAAP financial measures and a reconciliation of historical non-GAAP measures to historical GAAP measures. Safe Harbor This presentation includes express and implied "forward-looking statements", including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking stateme ...

Financial Performance - Product revenue reached $1.09 billion in Q2 FY26, representing a 32% year-over-year growth[53] - The company's net revenue retention rate was 125% in Q2 FY26[41] - Non-GAAP product gross margin was 76% in Q2 FY26[41] - Non-GAAP operating margin was 11% in Q2 FY26[75] - The company had 654 customers with over $1 million in product revenue, a 30% year-over-year growth[41, 67] - Remaining Performance Obligations (RPO) reached $6.93 billion, with 50% expected to be recognized as revenue in the next twelve months[57] Customer and Market Growth - The company's total customer base grew to 12,062[61] - Forbes Global 2000 customers increased to 751[63] - The company estimates its Total Addressable Market (TAM) has more than doubled[38] AI Data Cloud - 40% of customers have at least one stable edge in data sharing[85] - Marketplace listings grew by 21% year-over-year to 3,400[85] Fiscal Year 2026 Guidance - The company projects product revenue of $4.395 billion for FY26[88] - The company projects Non-GAAP operating margin of 9% for FY26[88]

Financial Performance - Q3 FY2025 - Revenue reached $1.74 billion, exceeding guidance by over $60 million[9] - Reported revenue growth was +10.1%[7, 11] - Core revenue growth was +6.1%[7, 16] - EPS was $1.37, a +4% year-over-year increase[7, 9] - Operating margin was 25.1%[7, 9] FY2025 Outlook - Core growth outlook raised to 4.5%[9, 14] - Revenue guidance increased by $150 million at the midpoint[9] - Net Revenue guidance is $6.91 to $6.93 billion[34] - EPS guidance is $5.56 to $5.59[34] Segment Performance - Q3 FY2025 - LDG (Life Sciences and Diagnostics Group) core growth was +14%[18] - ACG (Agilent CrossLab Group) core growth was +5%[18] - AMG (Agilent Molecular Spectroscopy Group) core growth was +7%[18] Revenue Breakdown - Americas accounted for 39% of Agilent's revenue[23] - Europe accounted for 28% of Agilent's revenue[23] - Asia-Pacific accounted for 33% of Agilent's revenue[23]

This presentation contains forward-looking statements based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, they could affect the business and results of operations of HP Inc. and its consolidated subsidiaries ("HP") which may differ materially from those expressed orimplied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements ...

Q4 FY2025 Earnings August 27, 2025 2 Safe Harbor Forward Looking Statements This presentation contains express and implied forward-looking statements, including, but not limited to, statements regarding: our business momentum and prospects, including our continued innovation across our cloud platform, including modern applications and AI; our first quarter fiscal 2026 outlook; and our fiscal 2026 outlook. Safe Harbor Non-GAAP Financial Measures and Other Key Performance Measures To supplement our consolidat ...

NASDAQ: MDBH We Launch Big Ideas Second Quarter 2025 Update August 27, 2025 FORWARD-LOOKING STATEMENTS & DISCLOSURES This presentation contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "pred ...

BILL NYSE BILL Investor Deck Aug 2025 Champions of small and midsize businesses. In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles GAAP, this presentation contains non-GAAP financial measures, including non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating income and non-GAAP net income. The non-GAAP financial information is presented for supplemental informational purposes only and is not intended to be consid ...

August 2025 z Investor Presentation Informe de resultados 1 Agenda | 01 | | 03 | 05 | 07 | | --- | --- | --- | --- | --- | | The | Argentine | Grupo Financiero | Naranja X | Fondos | | | | Galicia | | FIMA | | Economy | | | | | | 02 | | 04 | 06 | 08 | | The | Argentine | Banco | Galicia | Galicia | | Financial | System | Galicia | Seguros | Securities | Economic Activity 2,7% -2,1% 2,8% -2,6% -2,0% -9,9% 10,4% 6,0% -1,9% -1,3% 4,7% 3,5% -15% -10% -5% 0% 5% 10% 15% Real Gross Domestic Product % Change YoY 20 ...